Order prohibiting sale, supply, import of kava medicinal products will take effect in UK on January 13, Medicines Control Agency announces. Following examination of 70 reports of adverse liver reactions due to kava consumption - four cases resulting in death, seven in transplants - MCA "concluded that there is clear evidence linking kava...with rare cases of liver disease." However, agency notes it will review the ban in two years to assess whether it remains justified, and can review decision "at any time if new evidence emerges." The UK dietary supplement industry initially agreed to pull kava supplements from store shelves in December 2001 (1"The Tan Sheet" Dec. 24, 2001, p. 14)...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
If US tariffs on pharmaceutical supply chain products come into force they could be disruptive for companies. Ewan Townsend, of the international law firm Arnold & Porter, explains how companies can mitigate issues through negotiating with suppliers and reallocating tariff responsibilities.
The European Medicines Agency says that a regulatory reliance pilot that it is supporting to speed up assessments of post-approval changes appears to be accelerating evaluation timelines in non-EU countries.
The UK regulator’s draft guideline on the use of external control arms based on real-world data reflects concepts similar to those outlined by the US Food and Drug Administration.
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to include two new products, one of which is Vyjuvek, Krystal Biotech's advanced therapy for treating dystrophic epidermolysis bullosa.
If US tariffs on pharmaceutical supply chain products come into force they could be disruptive for companies. Ewan Townsend, of the international law firm Arnold & Porter, explains how companies can mitigate issues through negotiating with suppliers and reallocating tariff responsibilities.
Japan is cutting more drug reimbursement prices following cost effectiveness analysis and is applying the methodology to a new group of products including Wegovy and Leqembi.